# Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of venous thromboembolism

**Authors:** Erin Mathiesen Hald, Maja–Lisa Løchen, Kristian Hveem, Mary Cushman, Sigrid K. Brækkan, John–Bjarne Hansen

PMC · DOI: 10.1016/j.rpth.2025.102880 · Research and Practice in Thrombosis and Haemostasis · 2025-05-08

## TL;DR

This study shows that atrial fibrillation increases the risk of blood clots, and this risk is further raised by a specific genetic variant in people with the condition.

## Contribution

The study identifies that only the factor V Leiden variant increases VTE risk in atrial fibrillation, while other prothrombotic SNPs do not.

## Key findings

- Atrial fibrillation is associated with a 1.7-fold increased risk of venous thromboembolism.
- Factor V Leiden carriers with atrial fibrillation had a 1.9-fold higher VTE risk compared to non-carriers.
- Other prothrombotic SNPs did not increase VTE risk in individuals with atrial fibrillation.

## Abstract

Atrial fibrillation (AF) is a risk factor for venous thromboembolism (VTE), but the role of common prothrombotic gene variants in this relationship is unknown.

We investigated the joint effect of prothrombotic genotypes and AF on the risk of VTE in a population-based case-cohort.

Incident VTE cases (n = 1458) and a subcohort (n = 14,526) randomly sampled from the Tromsø (1994-2012) and Trøndelag Health (1995-2008) cohort studies were included. DNA was genotyped for rs8176719 (ABO), rs6025 (factor V Leiden [FVL]), rs1799963 (prothrombin), rs2066865 (fibrinogen gamma gene), and rs2036914 (F11). Hazard ratios (HRs) with 95% CIs for VTE were estimated by individual single-nucleotide polymorphisms and categories of a genetic risk score (0-1, 2, 3, 4, and ≥5 risk alleles) in subjects with and without AF.

Over a median 12.3 years follow-up, 1421 participants were diagnosed with AF, of whom 139 developed subsequent VTE. Overall, participants with AF had a 1.7-fold increased risk of VTE (HR, 1.73; 95% CI, 1.43-2.08). Among those with AF, ≥1 risk allele of FVL was associated with 1.9-fold higher VTE risk (HR, 1.89; 95% CI, 1.13-3.17) compared with 0 risk alleles. None of the other single-nucleotide polymorphisms increased the risk. In participants without AF, the VTE risk increased linearly with increasing genetic risk score. No such association was found for those with AF.

We confirmed that AF is a risk factor for VTE and showed that this relationship was augmented for carriers of FVL. Other common prothrombotic genotypes do not add additional risk of VTE to that induced by AF alone.

•We studied prothrombotic SNPs, AF, and risk of VTE.•In a large case-cohort, 5 genotypes were assessed individually and in a genetic risk score.•FVL was the only prothrombotic SNP associated with VTE risk in AF.•The 5-SNP genetic risk score did not add risk to the risk of VTE associated with AF.

We studied prothrombotic SNPs, AF, and risk of VTE.

In a large case-cohort, 5 genotypes were assessed individually and in a genetic risk score.

FVL was the only prothrombotic SNP associated with VTE risk in AF.

The 5-SNP genetic risk score did not add risk to the risk of VTE associated with AF.

## Linked entities

- **Genes:** ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) [NCBI Gene 28], F2 (coagulation factor II, thrombin) [NCBI Gene 395306], F11 (coagulation factor XI) [NCBI Gene 2160]
- **Diseases:** atrial fibrillation (MONDO:0004981), venous thromboembolism (MONDO:0005399)

## Full-text entities

- **Genes:** ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) [NCBI Gene 28] {aka A3GALNT, A3GALT1, GTA, GTB, NAGAT}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, F5 (coagulation factor V) [NCBI Gene 2153] {aka FVL, PCCF, RPRGL1, THPH2, fV}, F11 (coagulation factor XI) [NCBI Gene 2160] {aka FXI, PTA}
- **Diseases:** VTE (MESH:D054556), AF (MESH:D001281)
- **Mutations:** rs8176719, rs2036914, rs1799963, rs2066865, rs6025

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12272126/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12272126/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12272126/full.md

---
Source: https://tomesphere.com/paper/PMC12272126